Lantern Pharma在第25届LL&M大会上展示Lp-284临床数据,突显在疗法已耗竭的DLBCL患者中取得的完全反应及其在晚期B细胞癌症中的治疗潜力。
Lantern Pharma在第25届LL&M大会上展示Lp-284临床数据,突显在疗法已耗竭的DLBCL患者中取得的完全反应及其在晚期B细胞癌症中的治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.